Literature DB >> 17519276

Survival and causes of death in 366 Hungarian patients with systemic sclerosis.

L Czirják1, G Kumánovics, C Varjú, Z Nagy, A Pákozdi, Z Szekanecz, G Szucs.   

Abstract

OBJECTIVE: Survival analysis of a series of 366 consecutive patients with systemic sclerosis (SSc).
METHODS: Clinical and laboratory data were evaluated from 1983 until 2005 using a standard protocol. The female/male ratio was 315/51. The mean (SD) age of the patients was 56.8 (12.2) years. The duration of disease was 12 (5-19) years with a median follow-up of 6 (3-12) years.
RESULTS: Kaplan-Meier univariate analysis showed that renal, cardiac involvement, pigmentation disturbances, malabsorption, a forced vital capacity <50%, diffuse scleroderma, presence of early malignancy, anaemia, and increased erythrocyte sedimentation rate (ESR) were signs of unfavourable prognosis, whereas anti-centromere antibodies were indicators of a good survival. In the multivariate Cox proportional hazards model the presence of diffuse scleroderma, renal involvement, coexistence of a malignant disease, and increased ESR were poor independent prognostic signs. Elderly age at the onset of disease also caused an unfavourable outcome. A total of 86 SSc-related deaths were recorded during the follow-up. Of them, 65% were attributed to cardiorespiratory manifestation of disease. Tumour associated early death was found in 12 cases (14%).
CONCLUSIONS: In addition to the well-known factors influencing the outcome (diffuse subset, internal organ involvements, and inflammatory signs), the coexistence of scleroderma with a malignancy also causes a poor outcome.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17519276     DOI: 10.1136/ard.2006.066340

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  30 in total

Review 1.  N-TproBNP as biomarker in systemic sclerosis.

Authors:  Tommaso Schioppo; Carolina Artusi; Teresa Ciavarella; Francesca Ingegnoli; Antonella Murgo; Silvana Zeni; Cecilia Chighizola; Pier Luigi Meroni
Journal:  Clin Rev Allergy Immunol       Date:  2012-12       Impact factor: 8.667

Review 2.  [Clinical risk-adapted therapies in systemic sclerosis].

Authors:  G Riemekasten; D Dragun
Journal:  Z Rheumatol       Date:  2007-12       Impact factor: 1.372

Review 3.  Systemic sclerosis: a world wide global analysis.

Authors:  Paola Coral-Alvarado; Aryce L Pardo; Natalia Castaño-Rodriguez; Adriana Rojas-Villarraga; Juan-Manuel Anaya
Journal:  Clin Rheumatol       Date:  2009-03-11       Impact factor: 2.980

4.  Gastric slow waves, gastrointestinal symptoms and peptides in systemic sclerosis patients.

Authors:  T A McNearney; H S Sallam; S E Hunnicutt; D Doshi; D E Wollaston; M D Mayes; J D Z Chen
Journal:  Neurogastroenterol Motil       Date:  2009-06-30       Impact factor: 3.598

Review 5.  [Systemic sclerosis. Current classification and diagnosis of organ involvement].

Authors:  O D Persa; P Moinzadeh; N Hunzelmann
Journal:  Hautarzt       Date:  2015-08       Impact factor: 0.751

6.  Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma.

Authors:  Robyn T Domsic; Tatiana Rodriguez-Reyna; Mary Lucas; Noreen Fertig; Thomas A Medsger
Journal:  Ann Rheum Dis       Date:  2010-08-02       Impact factor: 19.103

Review 7.  Current developments in pediatric systemic sclerosis.

Authors:  Ivan Foeldvari
Journal:  Curr Rheumatol Rep       Date:  2009-04       Impact factor: 4.592

8.  The prognostic factors of systemic sclerosis for survival among Koreans.

Authors:  Jinhyun Kim; Sue Kyung Park; Ki Won Moon; Eun Young Lee; Yun Jong Lee; Yeong Wook Song; Eun Bong Lee
Journal:  Clin Rheumatol       Date:  2009-12-03       Impact factor: 2.980

Review 9.  Determinants of mortality in systemic sclerosis: a focused review.

Authors:  Dilli Ram Poudel; Divya Jayakumar; Abhijeet Danve; Shiv Tej Sehra; Chris T Derk
Journal:  Rheumatol Int       Date:  2017-11-07       Impact factor: 2.631

Review 10.  [Interdisciplinary point of contact between rheumatology and pneumology].

Authors:  J Hermann; G Kovacs; S Scheidl
Journal:  Z Rheumatol       Date:  2008-09       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.